ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
NCT05426850 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-06-22
Summary
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-01
- Primary Completion
- 2022-12-31
- Completion
- 2024-12-01
Countries
- China
Study Locations
More Related Trials
-
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
NCT06103890 ·Status: RECRUITING
-
Biomarkers and Functional Imaging in Predicting Response of Esophageal Cancer
NCT03029793 ·Status: UNKNOWN
-
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
NCT05028231 ·Status: UNKNOWN
-
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
NCT04694391 ·Status: UNKNOWN
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
NCT05628610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
NCT07162506 ·Status: RECRUITING ·Phase: PHASE2
-
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
NCT06601309 ·Status: RECRUITING ·Phase: PHASE2
-
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
NCT06490003 ·Status: RECRUITING
-
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
NCT07046221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342 ·Status: RECRUITING ·Phase: PHASE1
-
Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer
NCT07015489 ·Status: COMPLETED ·Phase: PHASE2
-
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
NCT05839002 ·Status: COMPLETED
-
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NCT05775419 ·Status: RECRUITING ·Phase: NA
-
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
NCT04764240 ·Status: COMPLETED
-
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT04568200 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
NCT06965829 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO
NCT04137679 ·Status: UNKNOWN ·Phase: PHASE2
-
Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma
NCT02446574 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
NCT05323890 ·Status: UNKNOWN ·Phase: PHASE2
-
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
NCT05142709 ·Status: COMPLETED
-
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
NCT02850991 ·Status: COMPLETED ·Phase: NA
-
Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer
NCT03120572 ·Status: COMPLETED
-
Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer
NCT04014465 ·Status: UNKNOWN
-
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
NCT02988921 ·Status: RECRUITING ·Phase: NA